My ePortfolio Register   

2017 ASCO Annual Meeting /
Global study sets new risk-based standard to personalise chemotherapy for colon cancer after surgery

2nd - 6th Jun 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.17
Views: 474
Rating:

Dr Axel Grothey - Mayo Clinic Cancer Centre, Rochester, USA

Dr Grothey presents, at a press conference at ASCO 2017, analysis from six medical trials with over 12,800 patients, finding that 3 months of chemotherapy was nearly as effective as 6 months in patients with relatively lower recurrence risk and caused fewer side effects, particularly nerve damage.

Read the news story for more. 

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence